Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: ER+ Breast Cancer|Ovarian Cancer|Cervical Squamous Cell Carcinoma|Pancreatic Adenocarcinoma|Endometrial Cancer|Renal Cell Carcinoma|Urothelial Cancer|Head and Neck Squamous Cell Carcinoma|Mesothelioma|Melanoma|Hepatocellular Carcinoma|Prostate Cancer|NSCLC|HER2-negative Breast Cancer|Triple Negative Breast Cancer|Bladder Cancer|Colorectal Cancer Metastatic|GastroEsophageal Cancer|NSCL2 Gene Mutation
Interventions: COMBINATION_PRODUCT: Obinutuzumab pretreatment (Gazyva®) Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)|COMBINATION_PRODUCT: Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)
Sponsor: NeoTX Therapeutics Ltd.
Collaborators: AstraZeneca